Screener
Agios Pharmaceuticals AGIO Deferred Tax Assets and Other Non-Current Assets
Deferred Tax Assets and Other Non-Current Assets at other companies
Other financials
Where this comes from
Reported directly by Agios Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:OtherAssetsNoncurrent.
The source filing: Agios Pharmaceuticals’s 10-Q, filed July 30, 2026.
- Filed
- Jul 30, 2026, 9:56 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001439222-26-000118
| (In thousands, except share and per share data) | June 30,2026 | December 31,2025 |
|---|---|---|
| Marketable securities | 347,254 | 310,013 |
| Operating lease assets | 23,875 | 30,454 |
| Property and equipment, net | 9,946 | 10,775 |
| Other non-current assets | 9,681 | 3,931 |
| Total assets | $1,108,424 | $1,297,225 |
| Liabilities and stockholders’ equity | ||
| Current liabilities: | ||
| Accounts payable | $16,345 | $18,355 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Agios Pharmaceuticals's deferred tax assets and other non-current assets?
- Agios Pharmaceuticals (AGIO) reported deferred tax assets and other non-current assets of $9.68M in Q2 2026.
- How has Agios Pharmaceuticals's deferred tax assets and other non-current assets changed year-over-year?
- Agios Pharmaceuticals's deferred tax assets and other non-current assets increased by 145.6% year-over-year, from $3.94M to $9.68M.
- What is the long-term trend for Agios Pharmaceuticals's deferred tax assets and other non-current assets?
- Over 5 years (2020 to 2025), Agios Pharmaceuticals's deferred tax assets and other non-current assets has grown at a 28.4% compound annual growth rate (CAGR), from $1.13M to $3.93M.
Ask your AI about Agios Pharmaceuticals's deferred tax assets and other non-current assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude